当前位置：首页 JCRQ2 期刊介绍(非官网)

Blood And Lymphatic Cancer-targets And Therapy

SCIE

国际简称：BLOOD LYMPHAT CANCER 参考译名：血液和淋巴系统癌症-靶点和治疗

中科院分区
3区
JCR分区
Q2

基本信息：: ISSN：1179-9889; 是否OA：未开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：United Kingdom; 出版商：Dove Medical Press; 出版语言：English; 出版周期：1 issue/year; 研究方向：ONCOLOGY

评价信息：: 影响因子：3.2

发文数据：: Gold OA文章占比：96.67%; 研究类文章占比：82.35%; 年发文量：17; 自引率：0.0714...; 开源占比：1; 出版撤稿占比：; 出版国人文章占比：0.06; OA被引用占比：1

投稿咨询加急见刊

英文简介期刊介绍中科院SCI分区 JCR分区发文数据常见问题

英文简介Blood And Lymphatic Cancer-targets And Therapy期刊介绍

Blood and lymphatic system cancers - targets and treatments "is a cutting-edge academic journal focused on research in the field of blood and lymphatic system cancers. With the global incidence rate of blood tumors (such as leukemia, lymphoma, etc.) rising year by year, the magazine came into being and is committed to promoting scientific research and clinical treatment progress in this field. Its published content covers various aspects of cancer, such as molecular mechanisms, novel therapeutic targets, innovative therapies, and clinical trials, providing researchers, clinical doctors, and patients with the latest scientific research achievements and diagnosis and treatment information. This magazine is published by authoritative institutions and undergoes rigorous peer review to ensure the scientific and reliable nature of its published content. As a professional journal in this field, 'Hematological and Lymphatic System Cancer - Targets and Treatment' plays an important role in promoting research and development in hematological oncology.

期刊简介Blood And Lymphatic Cancer-targets And Therapy期刊介绍

《Blood And Lymphatic Cancer-targets And Therapy》是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间：16 Weeks
医学
肿瘤学
SCIE
中科院3区
非预警

中科院SCI分区Blood And Lymphatic Cancer-targets And Therapy 中科院分区

《新锐期刊分区表》（2026年3月发布） 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	3区	ONCOLOGY 肿瘤学	3区

期刊分区表（2025年3月升级版） 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	2区	ONCOLOGY 肿瘤学	3区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Blood And Lymphatic Cancer-targets And Therapy JCR分区

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	ESCI	Q2	161 / 333	51.8
学科：ONCOLOGY	ESCI	Q3	181 / 333	45.8

2024-2025年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	ESCI	Q1	73 / 328	77.9
学科：ONCOLOGY	ESCI	Q3	184 / 328	44.05

2023-2024年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	ESCI	Q2	99 / 322	69.4
学科：ONCOLOGY	ESCI	Q3	188 / 322	41.77

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

国家/地区发文量统计

国家/地区数量
USA6
Italy3
Australia2
Spain2
CHINA MAINLAND1
England1
Iran1
Ireland1

本刊中国学者近年发表论文

1、Prognostic Value of the Aggregate Inflammation Systemic Index (AISI) in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Stud
Author: Chen, Xicheng; Huang, Linyu; Zhang, Qiming; Xing, Xing; Zhang, Shuo; Wang, Chunling; Wang, Ling; Shen, Ziyuan; Sang, Wei

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S571663
2、Construction and Validation of an N7-Methylguanosine-Related Prognostic Model for Acute Myeloid Leukemi
Author: Wang, Lina; Li, Ming; Xi, Yaming

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S575337
3、Crosstalk Between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therap
Author: Zhang, Jinjing; Jiang, Qiao; Liu, Tong; Li, Hong; Liang, Ying; Lu, Xianglan; Pang, Hui; Li, Shibo; Li, Yan; Zhang, Rui

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S571966
4、Safety and Efficacy of Flumatinib in Patients with Chronic Phase Chronic Myeloid Leukemia: A Real-Life Cohort Observational Stud
Author: Cheng, Fang; Cui, Zheng; Li, Qiang; Wang, Liu; Li, Weiming

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S573070
5、Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic lymphohistiocytosis-a Rare and Dangerous Diseas
Author: Meng, Guangqiang; Wang, Manzhi; Sun, Congcong; Feng, Gege; Ren, Jing; Feng, Saran; Wang, Yan

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S574445
6、Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 202
Author: Jin, Shi-Kai; Lyu, Jun-Ting; Feng, Zi-Yu; Zhang, Shu-Qi; Lu, Bin-Yan; Yan, Qin-Fu; Li, Jing; Du, Jun; Huang, Zou-Fang

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. 1-12. DOI: 10.2147/BLCTT.S556459
7、Study on the Role of Neutrophil Extracellular Traps-Based Risk Model and Discriminative Gene LTF in the Prognosis of Acute Myeloid Leukemia and the Regulation of Immune Microenvironmen
Author: Li, Yongjian; Zhang, Jingru; Liu, Tingting; Zhang, Di; Wang, Nana; Liu, Xiaomin; Feng, Panpan; Zhang, Juan; Ji, Chunyan; Ye, Jingjing

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S562651
8、A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insight
Author: Xie, Linzhi; Gao, Meng; Tan, Shiming; Zhou, Yi; Liu, Jing; Wang, Liwen; Li, Xin

Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2025; Vol. 15, Issue , pp. 21-37. DOI: 10.2147/BLCTT.S517354